<DOC>
	<DOCNO>NCT01644734</DOCNO>
	<brief_summary>To evaluate early ( 3-month ) impact long-acting anticholinergic Spiriva HH maintenance treatment COPD symptom use novel COPD Assessment test ( CAT ) real life set COPD patient , previously treat short-acting bronchodilator regular as-needed basis .</brief_summary>
	<brief_title>Assessment Health-status Patients With Chronic Obstructive Pulmonary Disease ( COPD ) Maintenance Therapy With Spiriva HH Measured COPD Assessment Test ( CAT ) Test</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : Male female ambulatory outpatient see participate physician office routine care , Patients clinical diagnosis COPD ( stage accord Global Initiative Chronic Obstructive Lung Disease ( GOLD ) guideline 2010 ) treat longacting anticholinergic ( Tiotropium , Spiriva® HandiHaler® ) maintenance therapy within product label maximum last 4 week ( 0.28. day Visit 1 ) , Patients previously treat shortacting bronchodilator regular asneeded basis least 3 month change longacting anticholinergic treatment , Patient fluent language questionnaire cognitive functional ability require fill questionnaire alone . Exclusion criterion : Uncooperative patient judge physician , Patients condition exclude per Country specific package insert , Patients currently enrol clinical trial , Patients COPD exacerbation acute disease last 3 month Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>